New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The...
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease The collaboration aims to identify and develop accessible...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo...
Biogen Completes Acquisition of Human Immunology Biosciences CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology...
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China China is the Third Country to Launch LEQEMBI Following the United States and JapanTOKYO and CAMBRIDGE, Mass...
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen...
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease TOKYO and...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Transaction to include felzartamab, a potential first-in-class...
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Development of BIIB105, an investigational antisense oligonucleotide for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 4.45 | 2.29027277406 | 194.3 | 199.05 | 194.3 | 28 | 196.95 | DE |
4 | -13.75 | -6.47058823529 | 212.5 | 220.7 | 194.3 | 37 | 209.93804348 | DE |
12 | -4.75 | -2.33415233415 | 203.5 | 220.7 | 194.3 | 29 | 210.00542169 | DE |
26 | -29.25 | -12.8289473684 | 228 | 229.2 | 177.65 | 33 | 205.04222786 | DE |
52 | -16.85 | -7.81539888683 | 215.6 | 244.6 | 177.65 | 29 | 207.59340408 | DE |
156 | -16.85 | -7.81539888683 | 215.6 | 244.6 | 177.65 | 29 | 207.59340408 | DE |
260 | -16.85 | -7.81539888683 | 215.6 | 244.6 | 177.65 | 29 | 207.59340408 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.